Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies

PURPOSE: Ras/Raf/MAPK kinase/ERK and rearranged in transformation (RET) kinase pathways are important in thyroid cancer. We tested sorafenib, a B-Raf, RET, and vascular endothelial growth factor receptor kinase inhibitor, combined with tipifarnib, a farnesyltransferase inhibitor that inactivates Ras...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hong, David S., Cabanillas, Maria E., Wheler, Jennifer, Naing, Aung, Tsimberidou, Apostolia M., Ye, Lei, Waguespack, Steven G., Hernandez, Mike, El Naggar, Alder K., Bidyasar, Savita, Wright, John, Sherman, Steven I., Kurzrock, Razelle
Formato: Artigo
Idioma:Inglês
Publicado em: Endocrine Society 2011
Assuntos:
Endocrine Care
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3070247/
https://ncbi.nlm.nih.gov/pubmed/21289252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2010-1899
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados